Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or...

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Vascular Endothelial Growth Factor (VEGF) and VEGF receptor 2 (VEGFR-2) signaling drive angiogenesis, contributing to gastric cancer progression.
• Ramucirumab is a monoclonal antibody targeting VEGFR-2.

Purpose of the Study:

• To evaluate if adding ramucirumab to first-line chemotherapy improves outcomes in metastatic gastric or gastro-oesophageal junction adenocarcinoma.
• To assess the efficacy and safety of ramucirumab in this patient population.

Main Methods:

• A double-blind, randomized, placebo-controlled, phase 3 trial involving 645 patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
• Patients received cisplatin plus capecitabine (or 5-FU) with either ramucirumab or placebo.
• Primary endpoint: investigator-assessed progression-free survival; Secondary endpoint: overall survival.

Main Results:

• Investigator-assessed progression-free survival was longer in the ramucirumab group (median 5.7 months vs 5.4 months), but this was not confirmed by central independent review (HR 0.961).
• Overall survival showed no significant difference between the ramucirumab and placebo groups (median 11.2 months vs 10.7 months).
• Common grade 3-4 adverse events included neutropenia and hypertension; serious adverse events were similar between groups.

Conclusions:

• The addition of ramucirumab to cisplatin plus fluoropyrimidine chemotherapy did not significantly improve overall survival in patients with metastatic gastric cancer.
• Due to the lack of confirmed progression-free survival benefit and no improvement in overall survival, ramucirumab is not recommended as a first-line treatment for this patient group.